A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of GLPG3667 in Adult, Healthy Male Subjects
Latest Information Update: 16 Feb 2022
At a glance
- Drugs GLPG 3667 (Primary)
- Indications Inflammation; Plaque psoriasis
- Focus Adverse reactions
- Sponsors Galapagos NV
- 11 Feb 2022 Status changed from recruiting to completed.
- 14 Oct 2021 Planned End Date changed from 1 Sep 2021 to 1 Jan 2022.
- 14 Oct 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Jan 2022.